These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31004652)

  • 1. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations.
    Jetzer MW; Morrical BD
    J Pharm Sci; 2019 Sep; 108(9):2949-2963. PubMed ID: 31004652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D; Kim J; Zhang J; Ke WR; Holl MMB; Chan HK
    Int J Pharm; 2023 Feb; 632():122563. PubMed ID: 36586629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.
    Zhang J; Khanal D; Chan HK; Banaszak Holl MM
    Int J Pharm; 2024 May; 656():124116. PubMed ID: 38615803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity.
    Elajnaf A; Carter P; Rowley G
    Eur J Pharm Sci; 2006 Dec; 29(5):375-84. PubMed ID: 16952450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of relative humidity on electrostatic charge decay of drugs and excipient used in dry powder inhaler formulation.
    Elajnaf A; Carter P; Rowley G
    Drug Dev Ind Pharm; 2007 Sep; 33(9):967-74. PubMed ID: 17891583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of secondary processing on the structural relaxation dynamics of fluticasone propionate.
    Depasquale R; Lee SL; Saluja B; Shur J; Price R
    AAPS PharmSciTech; 2015 Jun; 16(3):589-600. PubMed ID: 25398478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI).
    Rowland M; Cavecchi A; Thielmann F; Kulon J; Shur J; Price R
    Pharm Res; 2018 Nov; 36(1):15. PubMed ID: 30478630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols.
    Yu J; Wong J; Ukkonen A; Kannosto J; Chan HK
    Pharm Res; 2017 Aug; 34(8):1707-1715. PubMed ID: 28540500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J; Gill C; Young PM; Traini D
    Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.
    Young PM; Sung A; Traini D; Kwok P; Chiou H; Chan HK
    Pharm Res; 2007 May; 24(5):963-70. PubMed ID: 17377746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.